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Abstract
Background: Compound selectivity is an important issue when developing a new drug. In many instances, a lack of
selectivity can translate to increased toxicity. Protein kinases are particularly concerned with this issue because they
share high sequence and structural similarity. However, selectivity may be assessed early on using data generated from
protein kinase profiling panels.
Results: To guide lead optimization in drug discovery projects, we propose herein two new selectivity metrics, namely
window score (WS) and ranking score (RS). These metrics can be applied to standard in vitro data–including intrinsic
enzyme activity/affinity (Ki, IC50 or percentage of inhibition), cell-based potency (percentage of effect, EC50) or even
kinetics data (Kd, Kon and Koff). They are both easy to compute and offer different viewpoints from which to consider
compound selectivity.
Conclusions: We performed a comparative analysis of their respective performance on several data sets against
already published selectivity metrics and analyzed how they might influence compound selection. Our results showed
that the two new metrics bring additional information to prioritize compound selection.
Keywords: Selectivity, Protein kinase, Kinase inhibitor, Gini score, Entropy score, Partition index, Window score, Ranking
score
Background
The assessment of compound selectivity is of major
interest in drug discovery. This important parameter is
carefully monitored in drug discovery projects in order
to minimize the potential toxicity liabilities of com-
pounds. Selectivity assessment is often used in the defin-
ition of the Target Product Profile (TPP) of a lead to
highlight the need for an acceptable window between ac-
tivity on the biological target and off-target activities. An
insufficient selectivity profile is one of the reasons
underlying numerous failures in clinical trials [1]. Re-
search in the field of protein kinase inhibitors is particu-
larly impacted by this problem. The protein kinase
family represents more than 500 members of the human
proteome [2]. Due to the fact that they all share a well
conserved ATP binding site, the design of selective in-
hibitors remains a challenge and has negatively impacted
the progression of drug candidates to late-stage clinical
development. The recent failures in early clinical trials
of p38 MAPK inhibitors [3], as well as the difficulty of a
CDK inhibitor (dinaciclib, PD-0332991) to reach phase
III clinical trial [4] are noteworthy examples of the se-
lectivity issues in the kinase field. Nonetheless, several
studies have also shown that there are benefits to having
selective but not necessarily completely specific inhibi-
tors as drugs [5–7]. The success of multi-targeted kinase
inhibitors imatinib and gefitinib shows that the safety of
a drug does not rely exclusively on selectivity, as long as
the administered dose remains within the therapeutic
window [8–10]. Furthermore, a relative selectivity could
be of added value to a compound, bringing with it a po-
tentially advantageous polypharmacological profile [11].
For instance, dual inhibitors of the PI3K/mTOR pathway
have been found to be more efficient at inhibiting the
proliferation of breast cancer cells than specific inhibi-
tors of PI3K or mTOR [12, 13]. This demonstrates the
importance of studying the selectivity profile of com-
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Historically, attempts to evaluate protein kinase inhibi-
tor potency were only made on a reduced set of selected
kinases. Thanks to recent improvements in biochemical
assays, now there are a number of companies that offer
robust and reliable technologies for screening compound
collections on large kinase panels [14, 15]. Consequently,
a growing number of studies have been published de-
scribing broad kinase profiling, in which tens to hun-
dreds of compounds were tested on more than half of
the human kinome [16–19]. These have made available
to the scientific community a wealth of experimental
data: such as binding affinity or inhibition of functional
activity for the primary kinase target as well as the se-
lectivity profile of the compounds screened. However,
how the selectivity is defined or computed may highly
influence the perception of molecules of interest. In the
past decades, several selectivity metrics have been pub-
lished and used for research purposes [20–22]. Since
they differ significantly in their definition and complex-
ity, this impacts both their ease of understanding and
usability as well as the conclusions regarding compound
selectivity profiles.
In this study, we propose two new metrics, named
window score (WS) and ranking score (RS), to assess
compound selectivity and we compare their performance
on large kinase profiling data with four common select-
ivity scores commonly used in drug discovery: the stand-
ard selectivity score, the Gini coefficient, the selectivity
entropy and the partition index. In this study, compara-
tive assessment of the selectivity scores has been per-
formed on three different published datasets obtained
from different assay types. Two datasets were obtained
from enzymatic assays performed on a large fraction of
the kinome. For the third one, we used the results from
a cellular assay to assess the performance of these select-
ivity metrics. The proposed metrics provide novel in-
sights on the selectivity profile of tested molecules and
can be used in drug discovery projects as decision mak-
ing tools to help compound selection.
Methods
Datasets
Among all publicly available biological datasets contain-
ing protein kinases, we have selected the two datasets
having the highest percentage of completeness, i.e. the
interaction matrix is as complete as possible. Such a se-
lection is particularly important to ensure a reliable
comparison between various selectivity metrics. The first
dataset was provided by Davis et al. [16], in which 72 in-
hibitors were tested on 442 wild-type and mutated pro-
tein kinases (completeness of 100%). A dissociation
constant (Kd) was measured for each protein-ligand pair
only when an activity was first detected at 10 μM com-
pound concentration. Among the tested protein kinases,
we removed three bacterial proteins leading to a total of
439 protein kinases. The second dataset was published
by Anastassiadis et al. [17], where the percentage inhib-
ition of 178 compounds, tested at 0.5 μM, were mea-
sured on 300 wild-type and mutated protein kinases
(completeness of 99%).
The use of a unique metric to estimate the selectivity
of a compound across different datasets, regardless of
the experimental method used to generate these data
would be of great value. Indeed it would ease data ana-
lysis by avoiding activity unit conversions, and it would
provide a universal tool allowing the direct comparison
of different selectivity profiles. Although the experimen-
tal screening techniques used in both datasets are differ-
ent (competition binding assay [23] and “HotSpot” assay
[17]), we observed a relatively important overlap be-
tween the protein kinase–ligand pairs tested. This is why
these two datasets were used for direct comparison of
various selectivity scores. Therefore, we standardized
protein kinase names using the UniProt [24] identifier
and compound names using InChI [25] identifier in both
datasets for direct comparisons. We counted 4720 pairs
present in both publications (249 protein kinases and 19
compounds). For convenience, we will refer to the Davis
et al., and Anastassiadis et al. datasets, as Ambit and Re-
action Biology datasets respectively.
While most of the selectivity screening assays are per-
formed on recombinant enzymes in biochemical assays,
cellular assays can provide complementary information
such as signaling pathways, cellular potency and cell per-
meation [26]. Moreover, recent studies have shown that
assessment of compound selectivity using cellular or en-
zymatic assays may provide different results [27]. In
order to evaluate the broad applicability of our approach,
we have also studied the different selectivity scores on
cellular potencies. The NCI-60 Developmental Thera-
peutics Program Human Tumor Cell Line Screen was
initiated in the late 1980s. A total of 60 cell lines were
assembled to represent nine tumor types: breast, central
nervous system, colon, leukemia, lung, melanoma, ovar-
ian, prostate and renal [28]. Thousands of compounds
have been screened on this panel to estimate their po-
tency. Twenty-five protein kinase inhibitors approved by
the Food and Drug Administration (FDA) or in clinical
trials have already been tested on these cell lines. We
collected these data using CellMinerTM, a web applica-
tion developed by the Genomics and Bioinformatics
Group of the NCI [29, 30]. We will refer this dataset as
NCI-60 in the following text.
Selectivity metrics
Standard selectivity score (S)
For a given compound, the standard selectivity score S(x),
where x represents the activity threshold, is calculated by
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dividing the number of inhibited protein kinases having
an experimental value greater than x, by the total number
of tested protein kinases, as shown in the Eq. (1).
S xð Þ ¼ number of values≥x
total number of values
ð1Þ
Depending on the experimental method used in the
assay, x may also express a logarithmic affinity or activity
value. This metric is quantitative, easily computable and
comparable between different profiling results. In this
study, we have evaluated the variation of the standard se-
lectivity score, S(x), by using three different thresholds. For
the Ambit dataset we calculated S(pKd5), S(pKd6) and
S(pKd7) for 5, 6 and 7 logarithmic Kd thresholds respect-
ively. For the Reaction Biology dataset, we selected similar
range of activities S(50%), S(70%) and S(80%) for 50, 70
and 80% of inhibition relative to control thresholds re-
spectively. Finally for the NCI-60 data, we used the same
threshold as for the Ambit dataset. Hence, we calculated
S(pIC505), S(pIC506) and S(pIC507). In each example, a low
value of S(x) represents a high compound selectivity
whereas a high value of S(x) reflects a poor selectivity. The
thresholds were chosen to depict respectively low, medium
and high biological interaction with protein kinases.
The main drawback of this metric is the applied thresh-
old which needs to be defined and which has an important
impact on the final result. For instance, we can represent
the results of a profiling panel in which we take a com-
pound tested on 100 protein kinases. We calculate the
standard selectivity score S(pKd6) corresponding to a
threshold of six for pKd. If we count three proteins with
an affinity above the threshold, we may have apparently a
selective compound (three inhibited proteins out of 100).
Indeed, the S(pKd6) score would be 0.03. However this se-
lectivity score does not give any information on the
strength of binding of the compound and we would sup-
pose that the three inhibited proteins will have similar ef-
fects on cells. In contrast, with the same conditions and
three hits, we may have the situation where the ligand
shows nanomolar affinity for one target and just above the
threshold for another two. In this case, we would obtain
the same standard selectivity score, however this profile is
rather different. Whilst the compound binds all three pro-
teins selectively over the rest of the panel, there is a net
difference in affinity for the targeted proteins, with a con-
sequent divergence in impact at the cellular level.
Moreover, as recalled by Cheng et al. [21], the stand-
ard selectivity score does not capture any nuances. The
use of the threshold will split the data into two categor-
ies and even if the values are clustered around the
threshold, the protein kinases may well find themselves
grouped into distinct categories. Figure 1a illustrates this
specific issue where, in the proposed example, the pKd
threshold of seven sets kinase B (pKd = 7.2) and kinase C
(pKd = 6.8) in two different categories. While kinase A
(pKd = 8) is in the same category as kinase B, though these
two kinases have a larger affinity difference than kinase B
and C. This is an issue frequently encountered when using
a threshold for separating data and defining classes.
Gini coefficient (Gini)
The Gini selectivity metric (also known as the Gini coef-
ficient) is particularly well designed for percentage of
Fig. 1 Schematic representation of three selectivity metrics. a standard selectivity score; b window score; c ranking score. The x-axis represents
the protein kinases tested, the y-axis the activity of a given compound
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inhibition. According to Graczyk the data have to be
first sorted in ascending order to generate the curve of
the cumulative fraction of inhibition. The Gini coeffi-
cient is then calculated using the area under the curve.
For further details of the calculation, the reader may
refer to the original article [20]. Unlike the standard se-
lectivity score, this metric does not rely on any thresh-
old. However, the use of percentages of inhibition
instead of a constant of inhibition (Ki) or a dissociation
constant (Kd), makes the Gini coefficient highly
dependent on the experimental conditions. Since the
percentage of inhibition of a compound on a target is
strongly dependent on its concentration, the Gini coeffi-
cient may vary at different compound concentrations.
Partition Index (PI)
The Partition Index (PI) was developed to discriminate
selective compounds in small panels [21]. Using Kd
values and a thermodynamic approach (a concept simi-
lar to the one applied for the selectivity entropy), this
metric estimates the fraction of the binding of a com-
pound onto a reference protein kinase in comparison to
the remaining kinases in the panel. This metric returns
partition index values P ranging from 0 to 1. A com-
pound with a P value close to 1 would indicate a pro-
miscuous compound that binds almost every protein.
While this selectivity score is very useful within a unique
drug discovery project, the use of a reference protein
kinase to evaluate the partition index could be a limiting
factor if one wants to compare selectivity scores between
compounds from various projects having different pri-
mary targets. As mentioned by the authors, the partition
index is mainly suitable for a hit-to-lead process where
few selected proteins are used, but it may not be applic-
able for a larger protein panel. To override this issue, a
PMAX index was introduced to represent the inhibitor par-
titioning to the most potently inhibited protein kinase.
Selectivity entropy (Ssel)
The selectivity entropy (Ssel) is based on a thermody-
namics approach to measure compound selectivity [22].
The authors assume that the system contains theoretic-
ally all protein targets from the assay panel without any
competitive molecules such as ATP. Then the inhibitor
is added in such a way that it does not saturate any tar-
get, but all inhibitor molecules bind a target. In such
system, a selective inhibitor will bind approximately
one specific protein, so will have low entropy, while a
non-selective molecule will bind many targets and so
represents high entropy. Applying thermodynamic
principles, they translate this theory using the Boltz-
mann law and obtain a selectivity value based on the
entropy of the system.
Window score (WS)
The following two novel metrics, respectively window score
(WS) and ranking score (RS), require also a user-defined
threshold. Nevertheless, they both meet three essential con-
ditions. They take into account the ranking of the experi-
mental biological data and can be calculated easily. Indeed,
for a given compound, they rely on the distance separating
its maximum affinity (or activity) amongst all the biological
data from a user-defined affinity (or activity). Indeed, these
calculated distances are important for analyzing the select-
ivity profile of a hit selected for hit-to-lead progression. Im-
portantly, these two metrics can be applied on any data
types such as affinity or activity data. In the current study,
we applied the two selectivity scores on two datasets using
pKd and percentage of inhibition data respectively, but they
can also be used on other data types such as thermal stabil-
ity shift assays [19].
For a given compound in a dataset, the window score
requires the affinities to be ranked in descending order
(from the highest pKd value to the lowest). By choosing
a window threshold, we count all the affinity data points
that are included in the interval between the highest
pKd value and the highest pKd value minus the defined
window (Fig. 1b). This number is then divided by the
total number of tested proteins Eq. (2). Thus, the lower
the window score, the more selective the compound.
WS xð Þ ¼ number of affinities in window xð Þ
total number of affinities
ð2Þ
where window(x) represents the highest affinity minus
a user-defined affinity. The window score ranges from
almost zero (mathematically it cannot be lower than 1/
total no. of affinity data points) to one. The higher the
window score, the worse the selectivity. Similarly to the
standard selectivity score mentioned above, the window
score requires a threshold defined by the user. However,
this threshold is not abstract because it defines the activ-
ity gap one may want to obtain between the most inhib-
ited protein, often being the primary target, and the least
inhibited protein in the given window. To evaluate the in-
fluence of the threshold on the window score, we chose
three different windows: 2 log, 1 log and 0.5 log of Kd or
IC50 (respectively annotated WS(pKd2), WS(pKd1),
WS(pKd0.5) and WS(pIC502), WS(pIC501), WS(pIC500.5))
for the Ambit and the NCI-60 datasets respectively, and 20,
10 and 5% of inhibition (respectively annotated WS(20%),
WS(10%) and WS(5%)) for the Reaction Biology dataset.
Ranking score (RS)
For a given compound in a dataset, the ranking score
(RS) requires the affinity values to be ordered from the
highest to the lowest. By choosing a rank number, we
subtract the affinity value at the position defined by the
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rank number from the best affinity Eq. (3) (Fig. 1c).
Therefore, the higher the ranking score, the more select-
ive is the compound.
RS xð Þ ¼ max affinityð Þ −affinity at rank x ð3Þ
where x represents the affinity rank. As seen in Eq. (3),
a threshold also needs to be defined. The user only
needs to define the rank corresponding to the activity
difference between the activities of the xth inhibited pro-
tein and the most inhibited protein. In this study, we
evaluate the influence of the threshold on the ranking
score by selecting three different thresholds: 20, 10 and
5 (respectively RS(20), RS(10) and RS(5)) for the three
datasets. Since this score uses a rank number it is inde-
pendent of data types. Therefore, it can be applied for
comparing compound selectivity profiles from a panel of
proteins using various experimental techniques.
Results
In this paper, we introduced two new metrics, namely
window score (WS) and ranking score (RS), to assess the
selectivity of compounds tested on a large panel of pro-
tein kinases and we compared the results with previously
published selectivity scores. Comparative assessment of
the selectivity scores has been performed on three differ-
ent publicly available datasets. For each dataset, the cal-
culation of each of the aforementioned metrics was
performed with a Knime workflow (available upon re-
quest) and each molecule was then ranked according to
each metric.
Since the Gini coefficient, the selectivity entropy and the
partition index work exclusively with specific datatypes
(percentages of inhibition for the Gini coefficient and Kd/
Ki/IC50 for the two others) the calculation of all these
metrics for each dataset required that we converted the
data using an approximation of the Hill formula (4). As an
example, Eq. (4) was used to convert percentage of inhib-
ition to an approximate IC50:





where [c] is the compound concentration used for the
screening and %inh is the measured percentage of
inhibition.
Results from the Ambit dataset
The Ambit dataset contains 72 protein kinase inhibitors
tested on 441 protein kinases. For each pair, a quantita-
tive dissociation constant (Kd) was measured if the pri-
mary affinity was below the compound concentration of
10 μM. For the compounds for which primary activity in
the initial screen did not confirm, we assigned a value of
10.1 μM, considering the theoretical maximum affinity.
This approximation allows us to have a data matrix of pro-
tein–ligand pairs with a degree of completeness of 100%.
Thus, the selectivity scores calculated for all compounds
are performed on the same number of protein kinases. To
facilitate the comparison, all metrics have been ordered ac-
cording to WS(pKd2) (Additional file 1: Table S1).
Depending on the applied threshold values, some se-
lectivity scores cannot be computed. For instance, we
noticed two compounds (CI-1040, BMS-345541) for
which the standard selectivity score S(pKd7) could not
be calculated because the threshold was too high. As a
consequence, S(pKd7) was equal to zero since no protein
kinase was inhibited above this threshold. This illustrates
the concept that a compound may seem selective when
the applied cut-off is too high. In other words, a com-
pound may be inactive on protein kinases while the se-
lectivity score could suggest the opposite. To avoid any
confusion, we retained these compounds in the dataset
but did not assign them a rank (Additional file 1: Table
S1, empty cells). We compared the different metrics and
observed that none of them offers the same exact select-
ivity rank. The standard selectivity scores (S(pKd5),
S(pKd6) and S(pKd7)) present similar orders and it is
confirmed by their good pairwise correlation r > 0.85
based on their respective ranks (Fig. 2).
In the top four molecules selected from each selectiv-
ity score S(pKd5) and S(pKd6), we retrieved the same
four molecules namely GW-2580 [31], CI-1040 [32],
MLN-120B [33] and SGX-523 [34]. S(pKd7) presents the
same molecules at these positions except for CI-1040 be-
cause of the absence of strong affinity on the tested pro-
tein kinases. Indeed, despite a very high selectivity score
with S(pKd6), this compound presents a maximum
Fig. 2 Ambit selectivity metric correlations. Values from −1 (red) to
1 (blue)
Bosc et al. BMC Bioinformatics  (2017) 18:17 Page 5 of 12
affinity pKd of 6.9 on MAP2K1 amongst all protein ki-
nases. The correlation coefficient between S(pKd5) and
S(pKd7) is 0.85, slightly lower than the ones observed be-
tween S(pKd5) and S(pKd6), and S(pKd6) and S(pKd7)
(respectively 0.97 and 0.93, Fig. 2). This could be due to
the identification of several equally selective compounds
at high threshold value that prevent compound selectivity
discrimination. The novel metrics (window score and
ranking score) are also very sensitive to the threshold, but
have the advantage of being based on a maximum affinity
value. In that way, unlike the standard selectivity score,
they cannot return a zero value even with a stringent
threshold. We obtained similar ranking for WS(pKd2) and
WS(pKd1) (Fig. 2, r = 0.73), and for WS(pKd1) and
WS(pKd0.5) (Fig. 2, r = 0.75). However, a larger cut-off
variation involves important differences in the rankings
(Fig. 2, r = 0.37 between WS(pKd2) and WS(pKd0.5)).
While BMS-387032/SNS-032 [35], nilotinib [36] and
CHIR-265/RAF-265 are ranked respectively 14th, 24th
and 28th by WS(pKd2), they are all ranked first according
to WS(pKd0.5). Therefore, when the affinity rank x is high
these three compounds have simultaneously many affinity
values in the defined window. This is an advantage for this
metric that allows a rapid identification of the affinity win-
dow between the best hit and the next one. We observed
the same trend with the ranking score metric. The corre-
lations between the ranking scores are high when the
thresholds are similar while larger differences in the
threshold led to low correlations (Fig. 2, r = 0.45 between
RS(20) and RS(5), r = 0.64 between RS(20) and RS(10), r =
0.89 between RS(10) and RS(5)). Regarding the metric
Ssel, which does not use any threshold, it presents a good
correlation with several scores such as S(pKd7) (r = 0.63),
WS(pKd2) (r = 0.90), RS(20) (r = 0.87) and PMAX (r = 0.71).
PMAX is in good agreement with almost every other
metric, in particular with WS(pKd2) (r = 0.74), WS(pKd1)
(r = 0.86), WS(pKd0.5) (r = 0.79), RS(10) (r = 0.88), RS(5)
(r = 0.84) and Ssel (r = 0.71). In general, all metrics used in
this study seem to select the same molecules as being se-
lective, and the same molecules as being unselective, with
some specific differences in the ranking (Additional file 1:
Table S1). Interestingly, only the Gini coefficient presents
an anomalous ranking order with respect to the other
metrics, characterized by several correlation coefficients
below zero (Fig. 2).
When we analyzed the most selective compounds, we
retrieved GSK-461364A [37] at the top position with the
use of WS(pKd2), WS(pKd1), WS(pKd0.5), Ssel and
PMAX. SGX-523 [34] is at the top position with
WS(pKd0.5), RS(20), RS(10) and RS(5). PLX-4720 is
ranked first by the three window scores. It is important
to note that due to their mathematical form, some se-
lectivity scores will provide an identical score for several
molecules. MLN-120B is ranked first by S(pKd7),
WS(pKd1) and WS(pKd0.5). AZD-6244/ARRY-886 is
ranked first by S(pKd7), S(pKd6) and WS(pKd0.5). GW-
2580 [31] is ranked first by S(pKd5), WS(pKd1) and
WS(pKd0.5), though the global ranking of the com-
pounds over each metric is quite different. VX-745 [38]
is ranked first by S(pKd6), WS(pKd1) and WS(pKd0.5).
Some compounds show a good consensus among sev-
eral metrics. Indeed, we found that GSK-461364A, PLX-
4720, SGX-523, GDC-0879, BI-2536, CP-690550, GW-
2580 and VX-745 are in the top ten for at least eight se-
lectivity metrics. The selectivity entropy and the partition
index contain the same top three molecules, and their top
ten are in good agreement, but their rankings differ
slightly for the remaining molecules (Fig. 2, r = 0.71).
We noticed that the use of a cut-off for some metrics
can induce a lack of sensitivity for some molecules since
the same score is obtained for several molecules. We ob-
served this phenomenon mainly when a low cut-off
value was applied for the standard selectivity or the win-
dow score. For instance, two and three compounds are
ranked 13th and 14th respectively with S(pKd5). How-
ever, S(pKd6) identifies three compounds ranked first,
two compounds ranked second and four compounds
ranked 14th. Like the standard selectivity score, the win-
dow score can also suffer from this effect and 15 com-
pounds are ranked first by WS(pKd0.5). Analyzing the
affinities of these compounds, we noticed that their sec-
ond best affinity is outside the 0.5 window and so, their
respective window only contains one value, corresponding
to the best affinity. However, although they have the same
score, they do not bind the protein kinases with the same
promiscuity. The maximum pKd for INCB18424 [39] is
10.4 on JAK2 kinase domain, while for AZD-6244/ARRY-
886 [40] it is only seven on MAP2K1. Therefore,
WS(pKd0.5) is well designed to identify compounds that
bind preferentially to a protein kinase, but it is not suited
to distinguish highly from compounds with poor activity.
Interestingly, the Gini coefficient is the metric provid-
ing the largest ranking differences compared to all other
metrics (Fig. 2) with correlation values always close to 0
with the other metrics. As mentioned previously, this
could be related to the conversion of Kd to percentage
of inhibition, necessary to calculate the Gini coefficient
[22]. When we plot the values of the S(pKd5) against the
values of the Gini coefficients, we clearly see a parabolic re-
lation that cannot be caught by a linear correlation (Fig. 3).
Surprisingly, we noticed that staurosporine, known to
be a potent and unselective inhibitor of protein kinases
[23], is ranked third with WS(pKd0.5) and 12th with
WS(pKd1) (Additional file 1: Table S1) in contrast to the
other metrics that instead rank this molecule as highly
promiscuous. This clearly shows that the use of low
thresholds for selectivity scores can lead to erroneous
conclusions. In fact, staurosporine is ranked 47th, 55th
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and 61th by S(pKd7), S(pKd6) and S(pKd5) respectively.
Finally, vandetanib, a FDA-approved drug for EGFR and
VEGFR protein kinases, is classified as non-selective by
all selectivity metrics.
Results from the Reaction Biology dataset
The Reaction Biology dataset contains 178 protein kin-
ase inhibitors tested on 300 protein kinases. Percentages
of inhibition (instead of Kd) of each pair have been ob-
tained at a single 0.5 μM compound concentration.
Since the authors did not evaluate experimentally the in-
hibition profile for all protein-ligand pairs, the percent-
age of completeness is 99%. For the comparison between
all metrics, they all have been ordered according to
WS(10%) (Additional file 1: Table S2). As mentioned
previously, we noticed that some compounds do not
have activity greater than the thresholds of the standard
selectivity scores. Therefore, we have calculated the
twelve metrics on 109 out of the 178 compounds.
The analysis of the results shows a global trend for the
applied metrics. The color coding applied to Additional
file 1: Table S2 clearly shows that the same molecules
populate respectively the same ranking positions at the
top and bottom parts of the table for almost all metrics
except for the Gini coefficient, the selectivity entropy
and the partition index. Figure 4 shows good pairwise
correlations (r > 0.7) between the standard selectivity,
the window and the ranking scores. The Gini coefficient
shows low correlations with the other metrics though
they are still higher than with the previous dataset.
Hence, it seems that the Gini coefficient always ranks
compounds differently compared to other metrics inde-
pendent of the biological data type. PD 174265 is found
as the most selective compound by S(70%), S(80%),
WS(10%) and WS(5%). Moreover, this compound is
ranked in the top ten by four other metrics (S(50%),
WS(20%), RS(10) and RS(5)), and in the top 20 by three
other metrics (RS(20), Ssel and PMAX). Surprisingly, this
compound is ranked 131st by the Gini coefficient. The
compound mentioned in the article as an EGFR inhibi-
tor, presents a good consensus over the metrics. It is
systematically ranked in the top ten of the tested com-
pounds by all the metrics apart from PMAX (11th) and
Ssel (12th). Notably, it is ranked first by WS(20%) as well
as all the RS metrics independently of the used thresh-
olds. p38 MAP Kinase Inhibitor III seems also rather se-
lective as it is ordered first by S(70%), S(80%), WS(10%)
and WS(5%), and it appears in the top 20 for S(50%),
WS(20%), RS(20), RS(10). Similarly, tandutinib is ranked
first by S(70%), S(80%), WS(10%) and WS(5%) and in
the top 20 by WS(20%), RS(20), RS(10) and Gini score.
We retrieved the same first nine molecules using the
PMAX and Ssel metrics with almost identical order, but
these compounds are far from being the most selective
according to other metrics. As mentioned earlier, we
converted the percentages of inhibition into IC50 values
to calculate these two metrics. These transformed values
may be responsible for such important differences. The
Gini coefficient results in considerable ranking differ-
ences, as already reported [22].
Importantly, most of the metrics return the same set
of compounds as being promiscuous. Sunitinib [41],
SU11652 [42], JAK3 Inhibitor VI, GW 6976 [43], Indiru-
bin Derivative E804, PKR Inhibitor [44], CDK1/2 Inhibi-
tor II [45], SB 2180778 [46], K-252a [47] and
staurosporine are always ranked amongst the least se-
lective compounds by all metrics, except Ssel and PMAX.
This suggests that, in general, the metrics employing a
threshold show strong similarities in ranking compounds as
suggested by their correlation coefficients. This conclusion
differs slightly from what was observed with the Ambit
Fig. 3 Correlation between the Gini coefficients and the standard
selectivity score
Fig. 4 Reaction Biology selectivity metric correlations. Values from
−1 (red) to 1 (blue)
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dataset. This may be due to the use of percentage of inhib-
ition which does not fully discriminate inactive, weakly ac-
tive and highly active compounds compared to pKd or
pIC50. Therefore, the effect of the threshold used with per-
centage of inhibition (5, 10, 20, 50, 70 and 80%) has a lower
impact in discriminating selective compounds than pKd
(0.5, 1, 2, 5, 6 and 7). However, in both examples, the Gini
coefficient presents singular rankings. Since the Gini coef-
ficient is calculated using cumulative inhibition of the
compounds on the tested proteins, it is particularly sensi-
tive to compound concentration and to the number of
proteins screened.
Discussion
Selectivity metrics analysis of shared protein-ligand pairs
4720 protein-ligand pairs shared by Ambit and Reaction
Biology datasets were retrieved. This represents 19 mol-
ecules and 249 protein kinases. As a result of the afore-
mentioned threshold issue with the standard selectivity
scores, we could not calculate the selectivity of some
compounds using these metrics. The different rankings
according to the metrics and the datasets are available in
Additional file 1: Table S3.
Although we were interested in studying the impact of
the nature of the activity data used to rank compounds,
a direct consequence of the limited number of molecules
(19) for which datasets they were available, was the over-
sensitivity of the ranking to small variations in the data
when comparing two metrics. Initially, we focused on
the 19 molecules obtained from the Ambit dataset. Sub-
sequently, we applied similar analyses using only the Re-
action Biology dataset. Finally, we performed a pairwise
comparison of each metric and analyzed the influence of
the datasets. For the comparison we had to differentiate
the metrics that rely directly (Gini score, selectivity en-
tropy, partition index) or indirectly (standard selectivity
score, window score) on the type of measured activity.
Importantly, only the ranking score does not rely on ac-
tivity type.
The results obtained using Ambit data confirmed the
previous observations made on the full molecule set.
S(pKd5) S(pKd6) and S(pKd7) all present similar ranking
(Additional file 1: Table S3A) with pairwise correlations
of at least 0.83 (Fig. 5). We also noticed similar rankings
between WS(pKd2), RS(20), RS(10) and Ssel with good
pairwise correlations (r > 0.85). Additionally, Ssel pre-
sents excellent correlations with WS(pKd1) (r = 0.91)
and PMAX (r = 0.91).
Gefitinib is ranked first in six cases (S(pKd7),
WS(pKd2), WS(pKd1), WS(pKd0.5), Ssel and PMAX) and
always in the top five for all other metrics. The only ex-
ception is with the Gini coefficient that ranks this mol-
ecule 10th. Lapatinib [48] and GW-2580 are also ranked
systematically in the top five by the different metrics,
except by the Gini coefficient that ranks the two com-
pounds 19th and 18th respectively. Erlotinib appears ra-
ther selective in this panel since it is in the top five for
nine out of the 12 metrics [49]. A consensus appears for
staurosporine which is identified unselective by all calcu-
lated metrics. Finally, SKI-606 has an interesting profile
since it is considered more or less selective depending
on the metrics employed [50]. Indeed, with a pKd affin-
ity greater than eight on 45 out of 249 tested protein ki-
nases, the three standard selectivity scores rank this
molecule among the least selective compounds. Con-
trastingly, WS(0.5) ranks SKI-606 first because there is
only one activity present in the corresponding window.
More precisely, it shows a very high affinity on ABL1
(pKd = 10.2) and the second highest affinity is greater
than the 0.5 log threshold (pKd = 9.3 on MPK4K5). This
compound is also well ranked by WS(pKd1) (third),
RS(5) (6th), Gini (4th), Ssel (6th) and PMAX (4th). Hence,
SKI-606 clearly shows that the use of a selectivity score
is subjective and depends on the applied metrics. The
use of two different metric types such as RS or WS and
Gini, selectivity entropy or partition index, provides
greater confidence in the selectivity of a compound.
Regarding the 19 compounds from Reaction Biology
data, we observed a similar tendency with all the com-
pounds of this dataset (Additional file 1: Table S3B). Ex-
cept with the Gini coefficient, the selectivity entropy and
the partition index, all pairwise metrics correlate very
well (Fig. 5). We retrieved gefitinib, erlotinib, MLN-518
[51], SB-203580 [52], imatinib [53] and GW-2580, al-
most every time in the top five by the standard selectiv-
ity score and the window score. AB-1010 is ranked first
by the Gini coefficient, Ssel and PMAX but other metrics
rank this compound with a medium selectivity score
[54]. Standard selectivity, window and ranking scores are
in agreement in considering staurosporine, dasitinib [55]
and SKI-606 as poorly selective. Notably, Gini coeffi-
cient, Ssel and PMAX consider the PI3K inhibitor, PI-103
[56], as a promiscuous compound. PI-103 is a special
case since it has been designed to target an atypical fam-
ily of the kinome not present in the published dataset.
Therefore, it inhibits weakly most of the typical protein
kinases of the panel (no activity greater than 50%). How-
ever, WS(10%) and specially WS(5%) rank this com-
pound as particularly selective since an important
activity gap is observed between the first and second
most inhibited kinases (CSNK2A2 at 44% and NUAK2
at 25%). Interestingly, SKI-606, which was well ranked
by WS(pKd1) and WS(pKd0.5) on Ambit dataset, is
ranked last by the two equivalent metrics WS(10%) and
WS(5%) on Reaction Biology dataset .
Finally, to determine if one of these metrics could return
approximately a similar rank regardless of the dataset and
the measured activity type, we performed pairwise
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comparison of the compound ranks given by each metric
(Additional file 1: Table S3A and B). S(pKd5) and S(50%)
show a high correlation (r = 0.92), as do S(pKd6) and
S(70%) (r = 0.90) and S(pKd7) and S(80%) (r = 0.91) (Fig. 5).
Additionally, S(pKd7), computed on the Ambit dataset,
correlates with the standard selectivity scores, the window
scores and the ranking scores calculated on the Reaction
Biology dataset. S(pKd6) and S(pKd7) correlate better with
the window scores and the ranking scores calculated on
the Reaction biology dataset than with those calculated on
the Ambit dataset probably because the compounds have
been tested at 0.5 μM, and a 50% inhibition of a com-
pound roughly corresponds to a pIC50 (or pKd) of 6.3.
The window scores calculated on the Ambit dataset differ
slightly from those calculated on the Reaction Biology
dataset. When the threshold decreases for the window
score, the correlation between the two datasets decreases
also. For instance, the correlation between WS(pKd2) and
WS(50%) is equal to 0.75, but it decreases to 0.46 between
WS(pKd1) and WS(20%), and drops to zero between
WS(pKd0.5) and WS(10%) (Fig. 5).
Here again, this might be due to the correlation be-
tween pKd and percentage of inhibition ranges and a 2-
log, 1-log and 0.5-log gaps correspond to 50, 20 and 10%
activity gaps respectively. Regarding the ranking scores,
we noted some interesting correlations between the two
datasets using RS(20) (r = 0.74) and RS(10) (r = 0.71).
These medium correlations clearly show significant dif-
ferences in the selectivity results of the ranked com-
pounds when two types of experimental data are used.
Several outliers have also been identified [57]. A thorough
analysis on each compound reveals that the major differ-
ences come from the highest activities, as reflected by the
low correlation of the RS(5) (r = 0.34) between the two
datasets. Finally, as seen previously, there is no correlation
between the Gini coefficients calculated (r = −0.15), the
Ssel (r = 0.13) or the PMAX (r = 0.25) probably due to ac-
tivity data conversion necessary for these metrics (see
Methods). In conclusion, none of these three metrics
returns the same compound ranking when measured ac-
tivities are provided by different experimental techniques.
Nevertheless, the standard selectivity score and the win-
dow scores returned similar ranking for the 19 molecules
studied. It would be interesting to carry out this compari-
son on larger datasets to confirm this trend [58].
Selectivity analysis of kinase inhibitors from cellular
screening data
We evaluated the twelve metrics on cellular potencies
obtained from the US National Cancer Institute (NCI)
panel [28]. We retrieved 25 protein kinase inhibitors
tested on up to 60 human cancer cell lines. To avoid any
bias, we removed the inhibitor lestaurtinib since it was
tested on only 40 cell lines, and the melanoma cell line
MDA_N used by only two inhibitors. For each metric,
we ranked the 24 remaining protein kinase inhibitors
(Additional file 1: Table S4).
Firstly, each metric offers a unique rank. Imatinib was
ranked first or second by all metric except by the Gini
coefficient (6th). Nilotinib also presents a good selectiv-
ity on these cell lines [36]. It is present in the top three
of all metrics with the exception of S(pIC505) and Gini.
Fig. 5 Ambit–Reaction Biology overlap metrics correlations. Values from −1 (red) to 1 (blue)
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The results for bosutinib [50] and sunitib [42] show
greater contrast. These two compounds are scored sec-
ond and first by S(pIC507), WS(pIC501) and
WS(pIC500.5), fourth and third by RS(5), third and
fourth by PMAX, but 14th and 13th by S(pIC505), 14th
and 17th by Gini, and 10th and 12th by Ssel respectively.
Regarding the compounds with the lowest selectivity
scores, sorafenib [59] and trametinib seem to be the
least selective kinase inhibitors amongst the 24 kinase
inhibitors [60, 61]. It is important to note that the MEK
inhibitor trametinib is highly selective on the in-vitro
biochemical kinase panel [60]. Interestingly, sorafenib is a
drug approved by the FDA for the treatment of renal cell
and hepatocellular carcinoma and also for locally recur-
rent metastatic, progressive differentiated thyroid carcin-
oma. Nevertheless, in these assays, sorafenib inhibits the
59 tumor cell lines at less than 10 μM, but its maximum
inhibition is relatively high (1.25 μM on the breast cancer
cell line MDA_MB_231), the most sensitive cell line.
The correlation matrix allows the detection of novel
patterns regarding the differences in selectivity metrics
(Fig. 6). Firstly, the standard selectivity score S(pIC505)
poorly correlates with most of the metrics, even with the
S(pIC506) (r = 0.27) and S(pIC507) (r = 0). In contrast,
S(pIC507) shows a high correlation with most of the
other metrics, because these correlations were calculated
taking into account only compounds for which
S(pIC507) could be estimated (17 out of 24 compounds).
This is due to the reduced number of compounds with
high cell-based potency compared to those observed
with high activity in enzymatic assays. WS(pIC502) does
not correlate with any of the other window scores (r =
0.54 with WS(pIC501) and r = 0.23 with WS(pIC500.5))
due to unique profiles for some compounds. Hence,
bosutinib and sunitinib are ranked 11th and 14th re-
spectively with WS(pIC502) but second and first with
WS(pIC501) and WS(pIC500.5). An analysis of the bio-
logical profile of sunitinib shows that the highest po-
tency is on the KM12 cell line with a pIC50 of 7.4,
followed by HOP_92 with a pIC50 of 6.4. The presence
of only one potency in the 1 and 0.5 log windows for su-
nitinib explains its excellent rankings for WS(pIC501)
and WS(pIC500.5). However, we counted 47 out of 59
potencies in the 2 log window, resulting a poor selectiv-
ity score for WS(pIC502). There are excellent correla-
tions of 0.91 and 0.93 between WS(pIC502) and RS(20),
and WS(pIC502) and Ssel respectively. WS(pIC501) and
WS(pIC500.5) are both well correlated with RS(10),
RS(5) and in particular with PMAX (r = 0.92 and 0.87).
RS(20) shows similar ranking especially with WS(pIC502)
and Ssel, and to a lesser extend with RS(10) and PMAX.
RS(10) and RS(5) present good agreement with most of
the metrics except with S(pIC505) and the Gini coeffi-
cient. Actually, we observed here a new illustration of
the singularity of the Gini coefficient as it is in general
poorly correlated with most of the other metrics. Ssel
correlates well with WS(pIC502), WS(pIC501), RS(20),
RS(10) and PMAX. Finally, PMAX is without doubt the
metric correlating the most with the other metrics with r >
0.5 in all cases except with S(pIC505), S(pIC506) and Gini.
Therefore, the analysis of the twelve metrics on this
dataset containing tumor cell lines confirmed our previous
observations on the enzymatic dataset. Several metrics
seem to be unique in the way of identifying selective com-
pounds. The application of the metrics is highly
dependent on the expectations in drug discovery projects
and the selectivity profile is usually defined in the TPP.
Conclusions
The use of selectivity metrics in drug discovery projects
is an important parameter to assess the potential safety
profile of compounds, especially in the field of kinase re-
search. Several selectivity metrics were presented and
discussed using two large in vitro kinase profiling data-
sets and one cellular screening dataset. Two novel se-
lectivity scores, window score (WS) and ranking score
(RS) were developed and compared to existing metrics.
A key question was to see whether there might be a
clear metric that was definitively better in assessing
compound selectivity. Based on our study, currently the
answer would appear to be no. Although we have a pref-
erence for easily computable and understandable met-
rics, we think the choice of metric needs to be made
carefully. The use of several metrics may help in finding
a ranking consensus, but in this case, we suggest using
non correlated metrics, like the WS or RS with partition
index or selectivity entropy. The use of Gini coefficient
Fig. 6 NCI-60 selectivity metric correlations. Values goes from −1
(red) to 1 (blue)
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on a dataset containing many protein kinases should be
taken with caution. As observed in the analysis, its rank-
ing tends to be anomalous and not easy to understand,
independent of the dataset.
The standard selectivity score, along with the window
score and the ranking score have the advantage of being
very easy to compute. Therefore the results they provide
are simple to understand and to interpret. Nevertheless,
the threshold of the standard selectivity score may be at
the origin of some inconsistencies in the results when its
value is set too low, as emphasized during our analysis.
To avoid this issue, we recommend looking at the activ-
ity/affinity range before choosing the threshold. The
window score also required a threshold but its impact is
less pronounced than that of the standard selectivity
score. To differentiate compounds with these metrics,
we recommend using at least two different thresholds. A
narrow window will identify compounds that bind pref-
erentially one protein kinase, while a large cut-off will
identify this same compound if it does not bind many
other kinases in the corresponding window. The same
conclusion can be drawn for the ranking score. The se-
lected threshold has to represent the activity gap be-
tween two inhibited kinases that one considers large
enough for compound safety.
To compare two datasets obtained with various tech-
niques returning different activity types, the ranking score
is without doubt the metric of choice. As it is based only
on the rank determined directly by the data, it does not
require any data conversion that could lead to bias.
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